On September 15, 2022 Starpharma (ASX: SPL, OTCQX: SPHRY) reported that a presentation by Dr Jackie Fairley, CEO, will be broadcast on Thursday 15 September 2022 (US ET) as part of the US OTCQX’s Virtual Life Sciences Investor Forum (Press release, Starpharma, SEP 15, 2022, View Source;mc_eid=bf52dd3418 [SID1234619591]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Life Sciences Investor Forum is a leading investor conference that provides a forum for companies to present to tens of thousands of retail investors as well as advisors.

Details of the forum are found via this link: Virtual Life Sciences Investor Forum.

Starpharma’s pre-recorded presentation features a company overview, including:

the latest interim clinical trial results presented at ESMO (Free ESMO Whitepaper) oncology conference that show efficacy signals in 100% of prostate cancer patients assessed following DEP cabazitaxel treatment;
an overview of Starpharma’s DEP clinical-stage and preclinical assets, and corporate partnerships for its DEP drug delivery platform, including with Merck & Co., Inc (MSD) and AstraZeneca; and
a VIRALEZE overview and recent antiviral nasal spray results, including excellent protection against the SARS-CoV-2 Omicron variant, as well as updates on Starpharma’s portfolio more broadly.